Published in Neuromuscul Disord on June 21, 2009
METABOLIC FUNCTIONS OF MYOSTATIN AND GDF11. Immunol Endocr Metab Agents Med Chem (2010) 1.50
Role of TGF-β signaling in inherited and acquired myopathies. Skelet Muscle (2011) 1.28
Myostatin inhibition induces muscle fibre hypertrophy prior to satellite cell activation. J Physiol (2012) 1.16
Extracellular Regulation of Myostatin: A Molecular Rheostat for Muscle Mass. Immunol Endocr Metab Agents Med Chem (2010) 1.13
Hindlimb skeletal muscle function in myostatin-deficient mice. Muscle Nerve (2011) 1.07
Expression and function of myostatin in obesity, diabetes, and exercise adaptation. Med Sci Sports Exerc (2011) 1.03
Combination of myostatin pathway interference and dystrophin rescue enhances tetanic and specific force in dystrophic mdx mice. Mol Ther (2010) 1.01
Grip force, EDL contractile properties, and voluntary wheel running after postdevelopmental myostatin depletion in mice. J Appl Physiol (1985) (2010) 0.99
Is functional hypertrophy and specific force coupled with the addition of myonuclei at the single muscle fiber level? FASEB J (2011) 0.97
Targeted mutations in myostatin by zinc-finger nucleases result in double-muscled phenotype in Meishan pigs. Sci Rep (2015) 0.97
Relation between extent of myostatin depletion and muscle growth in mature mice. Am J Physiol Endocrinol Metab (2009) 0.96
Dual exon skipping in myostatin and dystrophin for Duchenne muscular dystrophy. BMC Med Genomics (2011) 0.92
Ubiquitous Gasp1 overexpression in mice leads mainly to a hypermuscular phenotype. BMC Genomics (2012) 0.85
Development of novel activin-targeted therapeutics. Mol Ther (2014) 0.85
Local overexpression of the myostatin propeptide increases glucose transporter expression and enhances skeletal muscle glucose disposal. Am J Physiol Endocrinol Metab (2014) 0.82
Effect of postdevelopmental myostatin depletion on myofibrillar protein metabolism. Am J Physiol Endocrinol Metab (2011) 0.81
Latent myostatin has significant activity and this activity is controlled more efficiently by WFIKKN1 than by WFIKKN2. FEBS J (2013) 0.80
Characterisation of connective tissue from the hypertrophic skeletal muscle of myostatin null mice. J Anat (2012) 0.76
Maltose binding protein-fusion enhances the bioactivity of truncated forms of pig myostatin propeptide produced in E. coli. PLoS One (2017) 0.75
Investigating mechanisms underpinning the detrimental impact of a high-fat diet in the developing and adult hypermuscular myostatin null mouse. Skelet Muscle (2015) 0.75
A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature (2007) 10.98
ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J (2011) 10.52
European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J (2003) 8.51
Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol (2009) 5.35
Defining knowledge translation. CMAJ (2009) 5.11
European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prev Rehabil (2003) 3.43
ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis (2011) 2.90
BSPAR Standards of Care for children and young people with juvenile idiopathic arthritis. Rheumatology (Oxford) (2010) 2.68
A comparison of the quality of Cochrane reviews and systematic reviews published in paper-based journals. Eval Health Prof (2002) 2.29
Lack of myostatin results in excessive muscle growth but impaired force generation. Proc Natl Acad Sci U S A (2007) 2.25
[ESC/EAS Guidelines for the management of dyslipidaemias]. Rev Esp Cardiol (2011) 2.21
Follistatin complexes Myostatin and antagonises Myostatin-mediated inhibition of myogenesis. Dev Biol (2004) 2.12
Current status of pharmaceutical and genetic therapeutic approaches to treat DMD. Mol Ther (2011) 2.06
Control of germination and lipid mobilization by COMATOSE, the Arabidopsis homologue of human ALDP. EMBO J (2002) 1.99
Identification of an emerging pathogen, Mycobacterium massiliense, by rpoB sequencing of clinical isolates collected in the United States. J Clin Microbiol (2007) 1.97
Adenovirus vector vaccination induces expansion of memory CD4 T cells with a mucosal homing phenotype that are readily susceptible to HIV-1. Proc Natl Acad Sci U S A (2009) 1.95
Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer. J Clin Oncol (2007) 1.91
Metabolic engineering of hydroxy fatty acid production in plants: RcDGAT2 drives dramatic increases in ricinoleate levels in seed oil. Plant Biotechnol J (2008) 1.82
[Calibrating the SCORE cardiovascular risk chart for use in Spain]. Rev Esp Cardiol (2007) 1.81
Variants at multiple loci implicated in both innate and adaptive immune responses are associated with Sjögren's syndrome. Nat Genet (2013) 1.79
Transmission of onchocerciasis in wadelai focus of northwestern Uganda has been interrupted and the disease eliminated. J Parasitol Res (2012) 1.76
Cardiovascular diseases in women: a statement from the policy conference of the European Society of Cardiology. Eur Heart J (2006) 1.73
A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum (2004) 1.71
Canonical Wnt signalling induces satellite-cell proliferation during adult skeletal muscle regeneration. J Cell Sci (2008) 1.68
Collaborative action around implementation in Collaborations for Leadership in Applied Health Research and Care: towards a programme theory. J Health Serv Res Policy (2013) 1.61
'I'm just short for my weight, doctor': body weight and risk. Eur J Cardiovasc Prev Rehabil (2011) 1.59
Exercise training attenuates the hypermuscular phenotype and restores skeletal muscle function in the myostatin null mouse. Exp Physiol (2011) 1.56
RNA-seq of Arabidopsis pollen uncovers novel transcription and alternative splicing. Plant Physiol (2013) 1.55
Muscle hypertrophy driven by myostatin blockade does not require stem/precursor-cell activity. Proc Natl Acad Sci U S A (2009) 1.55
ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis (2011) 1.51
Chronic systemic therapy with low-dose morpholino oligomers ameliorates the pathology and normalizes locomotor behavior in mdx mice. Mol Ther (2010) 1.48
2016 European Guidelines on cardiovascular disease prevention in clinical practice. Rev Esp Cardiol (Engl Ed) (2016) 1.42
Drug repositioning for Alzheimer's disease. Nat Rev Drug Discov (2012) 1.42
The reporting of theoretical health risks by the media: Canadian newspaper reporting of potential blood transmission of Creutzfeldt-Jakob disease. BMC Public Health (2004) 1.42
Implementing health research through academic and clinical partnerships: a realistic evaluation of the Collaborations for Leadership in Applied Health Research and Care (CLAHRC). Implement Sci (2011) 1.39
Transcriptome analysis shows activation of circulating CD8+ T cells in patients with severe asthma. J Allergy Clin Immunol (2011) 1.35
Micro-dystrophin cDNA ameliorates dystrophic phenotypes when introduced into mdx mice as a transgene. Biochem Biophys Res Commun (2002) 1.32
European guidelines on cardiovascular disease and prevention in clinical practice. Atherosclerosis (2003) 1.31
Re-evaluating the Rose approach: comparative benefits of the population and high-risk preventive strategies. Eur J Cardiovasc Prev Rehabil (2009) 1.28
How much does HDL cholesterol add to risk estimation? A report from the SCORE Investigators. Eur J Cardiovasc Prev Rehabil (2009) 1.28
Pax3 and Pax7 expression and regulation in the avian embryo. Anat Embryol (Berl) (2006) 1.26
A toolkit to facilitate the implementation of clinical practice guidelines in healthcare settings. Hosp Q (2002) 1.26
Development and evaluation of a decision aid for patients with stage IV non-small cell lung cancer. Health Expect (2000) 1.25
The effectiveness of interventions to reduce physician's levels of inappropriate transfusion: what can be learned from a systematic review of the literature. Transfusion (2002) 1.25
Supporting patients facing difficult health care decisions: use of the Ottawa Decision Support Framework. Can Fam Physician (2006) 1.24
Codon and mRNA sequence optimization of microdystrophin transgenes improves expression and physiological outcome in dystrophic mdx mice following AAV2/8 gene transfer. Mol Ther (2008) 1.24
Myostatin imposes reversible quiescence on embryonic muscle precursors. Dev Dyn (2006) 1.24
Poly(A) binding protein nuclear 1 levels affect alternative polyadenylation. Nucleic Acids Res (2012) 1.23
The regulation and action of myostatin as a negative regulator of muscle development during avian embryogenesis. Dev Biol (2002) 1.19
Dosing regimen has a significant impact on the efficiency of morpholino oligomer-induced exon skipping in mdx mice. Hum Gene Ther (2009) 1.19
Asymmetric dimethylarginine independently predicts fatal and nonfatal myocardial infarction and stroke in women: 24-year follow-up of the population study of women in Gothenburg. Arterioscler Thromb Vasc Biol (2008) 1.17
Screening for type 2 diabetes following gestational diabetes: family physician and patient perspectives. Can Fam Physician (2010) 1.15
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J (2016) 1.14
Safety and antiretroviral effectiveness of concomitant use of rifampicin and efavirenz for antiretroviral-naive patients in India who are coinfected with tuberculosis and HIV-1. J Acquir Immune Defic Syndr (2004) 1.14
Adeno-associated virus vector gene transfer and sarcolemmal expression of a 144 kDa micro-dystrophin effectively restores the dystrophin-associated protein complex and inhibits myofibre degeneration in nude/mdx mice. Hum Mol Genet (2002) 1.13
Current teaching of paediatric musculoskeletal medicine within UK medical schools--a need for change. Rheumatology (Oxford) (2009) 1.10
Molecular and phenotypic characterization of a mouse model of oculopharyngeal muscular dystrophy reveals severe muscular atrophy restricted to fast glycolytic fibres. Hum Mol Genet (2010) 1.10
Chromosomal context and epigenetic mechanisms control the efficacy of genome editing by rare-cutting designer endonucleases. Nucleic Acids Res (2012) 1.09
Smooth muscle-specific dystrophin expression improves aberrant vasoregulation in mdx mice. Hum Mol Genet (2006) 1.09
Prevalence, severity, and predictors of fatigue in subjects with primary Sjögren's syndrome. Arthritis Rheum (2008) 1.08
Gene correction of a duchenne muscular dystrophy mutation by meganuclease-enhanced exon knock-in. Hum Gene Ther (2013) 1.08
Follistatin regulates bone morphogenetic protein-7 (BMP-7) activity to stimulate embryonic muscle growth. Dev Biol (2002) 1.08
Simplifying cardiovascular risk estimation using resting heart rate. Eur Heart J (2010) 1.06
Skeletal muscle fibre plasticity in response to selected environmental and physiological stimuli. Histol Histopathol (2009) 1.05
Langerin negative dendritic cells promote potent CD8+ T-cell priming by skin delivery of live adenovirus vaccine microneedle arrays. Proc Natl Acad Sci U S A (2013) 1.05
Triple trans-splicing adeno-associated virus vectors capable of transferring the coding sequence for full-length dystrophin protein into dystrophic mice. Hum Gene Ther (2013) 1.04
Genes contributing to pain sensitivity in the normal population: an exome sequencing study. PLoS Genet (2012) 1.04
The water load test: observations from healthy controls and patients with functional dyspepsia. Am J Physiol Gastrointest Liver Physiol (2003) 1.04
Antisense-induced myostatin exon skipping leads to muscle hypertrophy in mice following octa-guanidine morpholino oligomer treatment. Mol Ther (2010) 1.03
The influence of experiential knowledge on prenatal screening and testing decisions. Genet Test (2008) 1.02
Titin-cap associates with, and regulates secretion of, Myostatin. J Cell Physiol (2002) 1.02
New developments in the use of gene therapy to treat Duchenne muscular dystrophy. Expert Opin Biol Ther (2013) 1.01
Guide to the assessment of competence and performance in practising surgeons. ANZ J Surg (2009) 1.01
Phase I study of dystrophin plasmid-based gene therapy in Duchenne/Becker muscular dystrophy. Hum Gene Ther (2004) 1.01
Gene therapy for muscular dystrophy: current progress and future prospects. Expert Opin Biol Ther (2009) 1.01
Medial patellofemoral ligament injury patterns and associated pathology in lateral patella dislocation: an MRI study. Sports Med Arthrosc Rehabil Ther Technol (2009) 0.99
Wnt6 controls amniote neural crest induction through the non-canonical signaling pathway. Dev Dyn (2007) 0.99